2020 VentureLaunch Winner

epiCaPture which is developing a novel urine DNA test for aggressive prostate cancer, was the overall winner of the 2020 UCD VentureLaunch Accelerator Programme. The epiCaPture test measures six epigenetic biomarkers which are indicative of aggressive disease, using a widely available PCR platform.

The epiCaPture test has potential as a non-invasive, early-detection and screening test to augment the current PSA blood test for the early-detection of aggressive prostate cancer. A second application is as a repeated use monitoring tool for men with low-grade disease, to identify tumour progression.

The members of the epiCaPture team, a early-stage venture emerging from the UCD School of Biology and Environmental Science are, Dr Antoinette Perry, Asia Jordan, Adele Connor and Ross Nelson, along with Edward Simons, a chartered accountant and former investment banker.